Salute e Benessere
BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial
The trial is designed to study BerGenBio's bemcentinib in combination with pacritinib, which is a JAK2 inhibitor indicated for treatment of the bone marrow disorder myelofibrosis in patients with platelet counts below 50 x 10 /L. It works by blocking certain growth factors and cytokines. Pacritinib is marketed in the United States as VONJO and owned by Swedish Orphan Biovitrum AB (Sobi ) (STO: SOBI), a specialized international biopharmaceutical company. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases.
The study will include patients with lung adenocarcinoma, the most common type of lung cancer in the United States , accounting for approximately 40% of all lung cancers. The study is funded by a grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
Olav Hellebø, CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie , CFO, BerGenBio ASA
rune.skeie@bergenbio.com
The trial sponsored by the Mays Cancer Center at The University of Texas Health Science Center at San Antonio is entitled "Study of Bemcentinib plus Pacritinib in Patients with Advanced adenocarcinoma" is a Phase Ib/II, open-label, single institution dose-escalation, safety, pharmacokinetics, pharmacodynamic and efficacy study. It is anticipated that a total of 44 patients will be enrolled in the trial. In the PhIb portion varying doses of bemcentinib and pacritinib will be studied in combination to determine safety, tolerability and the maximum tolerated dose. The Phase II portion of the trial will study the dose(s) selected in Phase Ib and will assess the overall response rate and progression free survival of treated patients.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK . The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-announces-first-patient-entered-into-advanced-adenocarcinoma-lung-cancer-trial,c4088137
View original content:https://www.prnewswire.co.uk/news-releases/bergenbio-announces-first-patient-entered-into-advanced-adenocarcinoma-lung-cancer-trial-302343911.html